Patent · US Active

HCV NS-3 serine protease inhibitors

US10172846B2 · kind B2 · utility

0Cited by

8References

21Claims

0Family size

Assignee

MEDIVIR AB · SE

Inventors

Asa Annica Kristina Rosenquist · Huddinge, SE
Fredrik Thorstensson · Linköping, SE
Per-Ola Mikael Johansson · Linköping, SE
Ingemar Kvarnstrom · Linköping, SE
Bertil Samuelsson · Huddinge, SE
Hans Wallberg · Stuvsta-Snättringe, SE

Key dates

Filing date	Mar 27, 2017
Grant date	Jan 8, 2019
Priority date	—
Expiry date	Apr 15, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2601/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.